Metronidazole Dosing and Toxicity in Dogs

Of course. Let's do a deep dive on metronidazole in dogs. It's a workhorse drug, but its reputation as a benign "anti-diarrhea" agent is undeserved given the risks at higher doses.

Here is a breakdown of its use, dosing, and toxicity profile.

Indications and Dosing

The key with metronidazole is that the dose varies significantly by indication. The "one size fits all" approach is what gets clinicians into trouble.

Serious Anaerobic Infections: For confirmed anaerobic infections (e.g., peritonitis, pyothorax, deep tissue abscesses), a dose of 15 mg/kg PO or IV q12h is appropriate. This provides systemic levels sufficient to penetrate tissues and exceed the MIC for most susceptible anaerobes like Bacteroides and Clostridium*.
Giardia intestinalis*: The traditional dose is 25 mg/kg PO q12h for 5-7 days. However, this is a high dose that carries an increased risk of neurotoxicity. Given that fenbendazole (50 mg/kg PO q24h for 5 days) has comparable efficacy and a much wider safety margin, it is now widely considered the first-line treatment. I would reserve metronidazole for cases of fenbendazole failure.
* Chronic Enteropathy / Antibiotic-Responsive Diarrhea (ARD): A lower dose of 10-15 mg/kg PO q12h is typically used. The goal here is often immunomodulatory or aimed at altering the dysbiotic microbiome rather than a true systemic antimicrobial effect. Therapy is often a 7-14 day trial. Long-term use should be avoided due to profound and lasting disruption to the gut microbiome.

Pharmacokinetics & Metabolism

Metronidazole is hepatically metabolized. This is a critical point. In patients with severe hepatic dysfunction or portosystemic shunts, clearance is dramatically reduced. This leads to drug accumulation and a significantly increased risk of toxicity. In these patients, a 50% dose reduction is my standard recommendation, coupled with close monitoring.

Neurotoxicity

Metronidazole neurotoxicity is a real and under-recognized risk. It's a function of both dose and duration.

* Clinical Signs: The syndrome is classic for central vestibular dysfunction. Look for:
* Acute onset of severe ataxia
* Positional nystagmus (often vertical, which is a red flag for a central lesion)
* Head tilt, leaning, falling
* Disorientation
* In severe cases, seizures can occur.
Risk Factors: The risk increases substantially at cumulative daily doses exceeding 60 mg/kg/day. The Giardia* dose (50 mg/kg/day) is right on this threshold, which is why we see toxicity most often in that context, especially if the course is prolonged. Patients with pre-existing hepatic disease are at much higher risk, even at lower doses.
* Management of Toxicity:
1. Discontinue the drug immediately. This is the most critical step.
2. Administer diazepam. The mechanism of toxicity is thought to involve modulation of GABAergic inhibitory pathways in the cerebellum and vestibular nuclei. Diazepam, a GABA-A agonist, directly counteracts this. A dose of 0.5 mg/kg IV can produce rapid clinical improvement, often within hours. This can be repeated as needed.
3. Provide supportive care. IV fluids, assisted feeding, and safe confinement are essential until the ataxia resolves.

Prognosis for recovery is generally good, but it can take anywhere from 24 hours to 2 weeks for signs to fully resolve after the drug is stopped and treatment is initiated. It's a valuable drug for true anaerobic infections, but we need to respect its therapeutic index.